Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies.
Andre Turenne brings to Voyager extensive strategic business development and commercial leadership experience, including nearly 12 years at Genzyme and Sanofi. He most recently served as Sanofi’s senior vice president, global head, business development and licensing, where he was responsible for partnering activities across all of Sanofi’s business units, including Sanofi Pasteur, Sanofi Genzyme, Diabetes-Cardiovascular, General Medicines and Consumer Health, and also served as Chair of the Sanofi Transaction Committee. He previously served as global head of strategy and business development at Genzyme following its acquisition by Sanofi. In addition to his extensive business development transactions and leadership positions, Mr. Turenne has held senior leadership positions at the country level as general manager of Sanofi Genzyme Australia/New Zealand with P&L responsibility for that region and at the global franchise level as head of commercial operations for the Renal and Endocrinology division, which achieved one billion dollars in annual revenues during his time. Mr. Turenne began his career in the industry as a consultant at Kendall Strategies, the consulting arm of Feinstein Kean Healthcare, now part of Ogilvy.
Mr. Turenne holds a B.A. from Kalamazoo College and an M.B.A. from the Tuck School of Business at Dartmouth.
Omar Khwaja brings to Voyager extensive research, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja joined Voyager from F. Hoffmann-La Roche AG (Roche), where he most recently served as Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases. During his seven years at Roche, Dr. Khwaja established an integrated discovery and development rare disease unit with clinical development in neuroscience. Within these groups, Dr. Khwaja led the initiation of Roche’s first clinical programs in gene therapy and delivered into pivotal trials multiple programs across various therapeutic modalities and indications including spinal muscular atrophy (SMA) and Huntington’s disease. Before joining Roche, Dr. Khwaja was Director of the Clinical Neurogenetics Program at Boston Children’s Hospital and on the faculty of Harvard Medical School.
Dr. Khwaja received his M.D. and Ph.D. from the University of Cambridge, Cambridge, UK. He trained in pediatrics and clinical genetics in London, UK and Melbourne, Australia and completed his neurology training at Massachusetts General Hospital and Boston Children’s Hospital, where he was Chief Resident. He is a Member of the Royal Colleges of Physicians of the United Kingdom and a Member of the Royal College of Pediatrics and Child Health.
Dinah Sah is our chief scientific officer. She has more than 20 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Sah has led multiple programs from early research through Phase 1 clinical trials, as well as discovering novel therapeutic targets and drug candidates that have advanced into clinical development. Before joining Voyager, Dr. Sah was at Alnylam Pharmaceuticals, where she was most recently vice president of research, providing scientific leadership and administrative oversight of discovery research and multiple research and development programs. At Alnylam, her leadership of several RNAi therapeutics R&D programs resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs. Prior to Alnylam, Dr. Sah was Associate Director of Research at Biogen, where she led neuroscience research and strategic planning for neurobiology, and before that, she headed neuroscience research at Signal Pharmaceuticals, where she also led multiple corporate partnerships and projects. Dr. Sah is an inventor on more than 25 patents, and her publications across diverse research areas include 18 articles in the New England Journal of Medicine, Nature Medicine, Nature Biotechnology, Nature Neuroscience, Nature Chemical Biology, Nature Reviews Drug Discovery, Molecular Therapeutics, Neuron, PNAS and EMBO Journal.
Dr. Sah received a Bachelor of Science in biology from the Massachusetts Institute of Technology, a Doctor of Philosophy in neurobiology from Harvard University and completed her postdoctoral training at Harvard Medical School.
Matthew Ottmer is our chief operating officer. He brings to Voyager more than 18 years of biotechnology industry experience, including executive leadership of business operations, product development, and commercialization across multiple therapeutic areas and all stages of development. Mr. Ottmer joins Voyager most recently from Momenta Pharmaceuticals, Inc., where he was chief operating officer, responsible for program and alliance management, research, clinical development, pharmaceutical sciences and commercial activities since late 2015. Prior to this role, he spent 16 years at Biogen, Inc., in a variety of leadership roles, including as senior vice president, strategy and emerging businesses, head of Tysabri business, chief of staff to the chief executive officer, president of Syntonix Pharmaceuticals, Inc. (a wholly owned subsidiary of Biogen, now Bioverativ, Inc.), and vice president of Global Operations.
Mr. Ottmer received a Bachelor of Arts in political science from the University of Michigan and a Master of Business Administration from Northwestern University’s Kellogg School of Management.
Luis Maranga joins Voyager with over 20 years of biotechnology industry experience, focused on bioprocess development, chemistry, manufacturing and controls (CMC), good manufacturing process (GMP), process validation and regulatory submissions, and facilities management including extensive work with the baculovirus/Sf9 expression system. Dr. Maranga most recently served as vice president, biologics development at Bristol-Myers Squibb Company (BMS), where he was responsible for all process and analytical development, and clinical manufacturing from post-discovery to commercial launch for BMS’s biologics programs, and where he also held previously the roles of general manager, Devens, MA; biologics commercial operations, site head for Hopkinton, MA site; and executive director, biologics manufacturing sciences and technology. Prior to BMS, Dr. Maranga served as head, technical development, viral vaccines at Novartis, and held senior R&D roles for biologics and vaccines at AstraZeneca/MedImmune and Merck & Co. Dr. Maranga is an expert on biologics, vaccines, and gene therapy CMC development and manufacturing.
DR. Maranga holds a Doctor of Philosophy in chemical engineering from Universidade Nova de Lisboa and a Bachelor of Science in chemical engineering from the Instituto Superior Tecnico both in Portugal.
Allison Dorval is our chief financial officer and serves as Voyager’s principal finance and accounting officer. She has over twenty years of corporate finance and accounting experience, including nine years of life sciences executive finance experience. Prior to Voyager, Ms. Dorval served most recently at Juniper Pharmaceuticals, Inc., and Insulet Corporation, where she led financial planning, reporting and accounting. Previously, Ms. Dorval held corporate finance positions with iBasis, Inc. and Digitas Inc. Ms. Dorval is a certified public accountant and began her career in public accounting at PricewaterhouseCoopers, LLP, where she held positions of increasing responsibility and scope.
Ms. Dorval obtained a Bachelor of Science in Business Administration (accounting concentration) from the University of Vermont.
Robert Hesslein is our general counsel, and his experience includes more than 25 years as an in-house attorney leading and building legal organizations within the biotechnology industry, with specific expertise in domestic and international commercial law, securities and public company reporting, medical data privacy, as well as licensing and business development collaborations. Mr. Hesslein joins Voyager from Foundation Medicine (acquired by Roche in July 2018), where he served as senior vice president, general counsel and chief compliance officer since 2012, responsible for managing corporate governance and all legal matters related to Foundation Medicine’s business including commercial, corporate and business development, compliance, and research and development functions. Prior to Foundation Medicine, Mr. Hesslein was a senior vice president and deputy general counsel at Genzyme Corporation (acquired by Sanofi in April 2011), serving in increasingly senior roles for 16 years, managing the legal support for many of Genzyme’s most significant transactions and establishing and leading Genzyme’s legal support outside of the U.S. Mr. Hesslein began his legal career at Csaplar & Bok (acquired by Gaston & Snow in 1990), a Boston-based law firm where he spent eight years as an associate and four years as a partner.
Mr. Hesslein earned a B.A. from Yale University and received his J.D. from The Cornell Law School.
Kathleen Hayes is our vice president of human resources. She has more than 25 years of experience in human resource leadership. Prior to Voyager, Ms. Hayes was the vice president of human resources for Insulet Corporation, where she led global initiatives focused on leadership development, culture, core values, recruiting and operations. Prior to Insulet, she held senior human resources roles for Outcome Sciences, PerkinElmer and Viacell.
Ms. Hayes received her Bachelor of Art from the University of Massachusetts and her Master of Business Administration from Boston University.
Robert Pietrusko is our senior vice president of regulatory affairs and quality assurance. He has three decades of experience in regulatory affairs and pharmaceutical drug development across a wide range of therapeutic categories, including CNS disorders and products governed by the Center for Biologics Evaluation and Research (CBER) of FDA. Dr. Pietrusko has directed the worldwide approval of more than 30 new products and new indications and is a recognized leader in the pharmaceutical industry having served as a BIO representative for PDUFA III and IV reauthorization negotiations with FDA. Before joining Voyager, Dr. Pietrusko was vice president of global regulatory affairs & quality and an executive officer at ViroPharma, Inc. where he played a key role in the company’s acquisition and regulatory approvals of Cinryze, a plasma-derived orphan drug product for the treatment and prevention of angioedema attacks. Before ViroPharma, Dr. Pietrusko was senior vice president of regulatory affairs at Millennium Pharmaceuticals, where he directed the strategy and accelerated approval of Velcade in the U.S. and in more than 90 countries worldwide, including the centralized procedure in the EU. Prior to Millennium, he was a Vice President of Regulatory Affairs at SmithKline Beecham (now Glaxo SmithKline), where he led the submission and approval strategies for more than 30 NDAs, sNDAs, BLAs and MAAs in multiple therapeutics areas. Dr. Pietrusko is the author or co-author of 52 scientific publications.
Dr. Pietrusko holds a Bachelor of Science in biology, a Bachelor of Pharmacy from Rutgers University, and a Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He completed his residency training in hospital pharmacy at Thomas Jefferson University Hospital.
Matthew Osborne is our vice president of corporate affairs, communications and investor relations. His healthcare career spans more than 20 years, including 17 years of biotechnology, Wall Street, and corporation communications and investor relations experience. During this time, Matt managed companies through the capital markets raising more than $3 billion in equity and debt transactions and provided strategic scientific platform, clinical, commercial and corporate communications across all stages of development, including during mergers and acquisitions, for multiple stakeholders.
Mr. Osborne’s industry experience includes global head of investor relations at Shire during its acquisition of Baxalta and Dyax, vice president of corporate communications and investor relations at Synageva BioPharma from its public inception through to its acquisition by Alexion, and investor relations at Vertex Pharmaceuticals during its transition from a research to commercial stage company, and as part of an institutional investor’s highly-ranked investor relations team. On Wall Street, as a biotechnology sell-side analyst at Lazard and Leerink Partners, among others, Mr. Osborne covered small to large cap biotechnology companies and analyzed several blockbuster drug launches across multiple therapeutic areas and launched several IPOs.
Mr. Osborne received a Bachelor of Science in biology from Syracuse University and a Master of Business Administration from the D’Amore-McKim School of Business at Northeastern University.
Allen Nunnally is our vice president of corporate and business development. His life sciences experience spans more than 16 years with a focus on genetically- and genomically-driven technologies and biopharmaceuticals at organizations ranging from Fortune 500 pharma companies to early-stage biotechs. Prior to Voyager, Mr. Nunnally served as vice president of corporate and business development and associate general counsel at Foundation Medicine, where he led transactions relating to its biopharmaceutical business in companion diagnostics, comprehensive genomic profiling, clinical trials solutions, and molecular information products and directed the company’s intellectual property strategy. Mr. Nunnally represented Foundation Medicine from Series B financing through its IPO and co-led the R&D collaboration of the company’s strategic transaction with Roche. Mr. Nunnally previously spent 10 years at the law firm Wilmer, Cutler, Pickering, Hale and Dorr LLP.
Mr. Nunnally received a B.A. in biology and law, jurisprudence and social thought from Amherst College and a JD from Boston University School of Law, where he concentrated in intellectual property law.